Cytisine for nicotine addiction treatment: a review of pharmacology, therapeutics and an update of clinical trial evidence for smoking cessation
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Aims: To review cytisine's history of use, pre‐clinical evidence, clinical pharmacokinetics, efficacy, adverse reactions (ARs) and safety for smoking cessation. Methods: A synoptic review of the use of cytisine as a smoking cessation medication, mechanism of action, pharmacokinetics and safety. Relevant literature on data included in these sections were identified through a search of 11 databases with additional literature obtained from reports and monographs. Three databases (PubMed, EMBASE and www.elibrary.ru) were systematically searched for studies published from 2012 to August 2018 in any language to provide an updated meta‐analysis of cytisine's efficacy and ARs for smoking cessation compared with placebo. We pooled the relative risks (RR) of abstinence in the efficacy analysis and RR of ARs, either reported by the authors or calculated from the reports. Results: Cytisine has been in use since 1964 and is currently marketed in 18 countries. Systemic bioavailability from oral ingestion is high and clearance is primarily renal, with minimal or no metabolism. Brain uptake in animal models is moderate. The plasma half‐life averages 4.8 hours. Eight studies were included for meta‐analysis of efficacy. With heterogeneous results, the overall RR versus placebo of successful continuous abstinence at the longest follow‐up was 1.74 [95% confidence interval (CI) = 1.38–2.19]. Nausea, vomiting, dyspepsia, upper abdominal pain and dry mouth that were mild or moderate were the most common ARs, with RR versus placebo 1.10 (95% CI = 0.95–1.28). The cost of cytisine in eastern and central Europe is several‐fold less than that of other smoking cessation medications. Conclusions: Cytisine is a low‐cost medication found to increase the likelihood of smoking cessation. The most frequently reported ARs of cytisine involve gastrointestinal symptoms that are mostly reported as either mild or moderate in severity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hao (2015) · doi:10.1002/14651858 · Cited by 11,321
21st-Century Hazards of Smoking and Benefits of Cessation in the United States
Jha, P., Ramasundarahettige, C., Landsman, V., Rostron, B., Thun, M., Anderson, R. N., McAfee, T., & Peto, R. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1211128 · Cited by 1,767
Benowitz, N. L. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0809890 · Cited by 1,508
Self-citationVarenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., Sands, S. B., Davis, T. I., Lebel, L. A., Fox, C. B., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050069n · Cited by 930
The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine
Corrigall, W. A., Franklin, K. B. J., Coen, K. M., & Clarke, P. B. S. (1992) · Psychopharmacology · doi:10.1007/bf02245149 · Cited by 829
The effects of nicotine on locomotor activity in non‐tolerant and tolerant rats
Clarke, P. B. S., & Kumar, R. (1983) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1983.tb09398.x · Cited by 457
Placebo-controlled trial of cytisine for smoking cessation
West, R., Zatonski, W., Cedzynska, M., Lewandowska, D., Pazik, J., Aveyard, P., & Stapleton, J. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102035 · Cited by 234
Rollema, H., Shrikhande, A., Ward, K., Tingley III, F., Coe, J., O'Neill, B., Tseng, E., Wang, E., Mather, R., Hurst, R., et al. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00682.x · Cited by 162
Grady, S. R., Murphy, K. L., Cao, J., Marks, M. J., McIntosh, J. M., & Collins, A. C. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.2.651 · Cited by 110
Stapleton, J. A., & West, R. (2012) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntr236 · Cited by 62
Cited by
Current advances in research in treatment and recovery: Nicotine addiction
Prochaska, J. J., & Benowitz, N. L. (2019) · Science Advances · doi:10.1126/sciadv.aay9763 · Cited by 219
Self-citationEffect of Cytisine vs Varenicline on Smoking Cessation: A Randomized Clinical Trial
Courtney, R. J., McRobbie, H., Tutka, P., Weaver, N. A., Petrie, D., Mendelsohn, C. P., Shakeshaft, A., Talukder, S., Macdonald, C., Thomas, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.7621 · Cited by 118
Self-citationGajendra, S., McIntosh, S., & Ghosh, S. (2023) · Tobacco Induced Diseases · doi:10.18332/tid/157203 · Cited by 89
Metadata
- Authors
- Tutka, P., Vinnikov, D., Courtney, R. J., & Benowitz, N. L.
- Venue
- Addiction
- Publisher
- Wiley
- Published
- 2019-07-19
- Volume
- 114
- Issue
- 11
- Pages
- 1951-1969
- ISSN
- 0965-2140 (ISSN-L)
- 1360-0443
- OpenAlex
- W2955293132
- Cited by
- 121
- References
- 11
- FWCI
- 6.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.